Antisense approaches for inhibiting respiratory syncytial virus
Author: Hagen Cramer
Source: Expert Opinion on Biological Therapy, Volume 5, Number 2, 1 February 2005 , pp. 207-220(14)
Publisher: Informa Healthcare
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Respiratory syncytial virus (RSV) continues as an emerging infectious disease not only among infants and children, but also for the immune-suppressed, hospitalised and the elderly. To date, ribavirin (Virazole®, ICN Pharmaceuticals, Inc.) remains the only therapeutic agent approved for the treatment of RSV. However, its clinical benefits are small and occur only in a fraction of RSV-infected patients. The prophylactic administration of palivizumab (Synagis, MedImmune, Inc.) is problematic and costly and, therefore, only recommended for use in high-risk infants. Clearly, the need for an effective and safe drug remains high. This review discusses several different antisense approaches and compares them with traditional strategies, such as RSV-targeting antibodies and antivirals, as well as developments in vaccine research.Keywords: 2-5A; 2-5A antisense; antisense; antivirals; aptamer; interferon; oligonucleotide; oligodeoxyribonucleotide; palivizumab; phosphorothioate; ribavirin; RNase L; siRNA
Document Type: Review article
DOI: 10.1517/14712598.5.2.207
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content

Click here for Page Help